Literature DB >> 24803830

One case of intrahepatic cholangiocarcinoma amenable to resection after radioembolization.

Cecilia Servajean1, Marine Gilabert1, Gilles Piana1, Geneviève Monges1, Jean-Robert Delpero1, Isabelle Brenot1, Jean-Luc Raoul1.   

Abstract

We report the case of a 57-year-old man who was diagnosed with a large unresectable cholangiocarcinoma associated with 2 satellite nodules and without clear margins with the right hepatic vein. Despite 4 cycles of GEMOX (stopped due to a hypertransaminasemia believed to be due to gemcitabine) and 4 cycles of FOLFIRINOX, the tumor remained stable and continued to be considered unresectable. Radioembolization (resin microspheres, SIRS-spheres) targeting the left liver (474 MBq) and segment IV (440 MBq) was performed. This injection was very well tolerated, and 4 more cycles of FOLFIRINOX were given while waiting for radioembolization efficacy. On computed tomography scan, a partial response was observed; the tumor was far less hypervascularized, and a margin was observed between the tumor and the right hepatic vein. A left hepatectomy enlarged to segment VIII was performed. On pathological exam, most of the tumor was acellular, with dense fibrosis around visible microspheres. Viable cells were observed only at a distance from beads. Radioembolization can be useful in the treatment of cholangiocarcinoma, allowing in some cases a secondary resection.

Entities:  

Keywords:  Combined treatments; Intrahepatic cholangiocarcinomal; Radioembolization; Surgery

Mesh:

Substances:

Year:  2014        PMID: 24803830      PMCID: PMC4009552          DOI: 10.3748/wjg.v20.i17.5131

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  10 in total

Review 1.  Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment.

Authors:  Boris Blechacz; Gregory J Gores
Journal:  Hepatology       Date:  2008-07       Impact factor: 17.425

Review 2.  Cholangiocarcinoma.

Authors:  Shahid A Khan; Howard C Thomas; Brian R Davidson; Simon D Taylor-Robinson
Journal:  Lancet       Date:  2005-10-08       Impact factor: 79.321

3.  Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.

Authors:  Juan Valle; Harpreet Wasan; Daniel H Palmer; David Cunningham; Alan Anthoney; Anthony Maraveyas; Srinivasan Madhusudan; Tim Iveson; Sharon Hughes; Stephen P Pereira; Michael Roughton; John Bridgewater
Journal:  N Engl J Med       Date:  2010-04-08       Impact factor: 91.245

4.  Hepatic resection and transplantation for peripheral cholangiocarcinoma.

Authors:  F A Casavilla; J W Marsh; S Iwatsuki; S Todo; R G Lee; J R Madariaga; A Pinna; I Dvorchik; J J Fung; T E Starzl
Journal:  J Am Coll Surg       Date:  1997-11       Impact factor: 6.113

5.  Volumetric changes after (90)y radioembolization for hepatocellular carcinoma in cirrhosis: an option to portal vein embolization in a preoperative setting?

Authors:  Julien Edeline; Laurence Lenoir; Karim Boudjema; Yan Rolland; Anne Boulic; Fanny Le Du; Marc Pracht; Jean-Luc Raoul; Bruno Clément; Etienne Garin; Eveline Boucher
Journal:  Ann Surg Oncol       Date:  2013-03-15       Impact factor: 5.344

6.  Yttrium-90 radioembolization for intrahepatic cholangiocarcinoma: safety, response, and survival analysis.

Authors:  Samdeep Mouli; Khairuddin Memon; Talia Baker; Al B Benson; Mary F Mulcahy; Ramona Gupta; Robert K Ryu; Riad Salem; Robert J Lewandowski
Journal:  J Vasc Interv Radiol       Date:  2013-04-19       Impact factor: 3.464

7.  Yttrium-90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: a preliminary assessment of this novel treatment option.

Authors:  Akshat Saxena; Lourens Bester; Terence C Chua; Francis C Chu; David L Morris
Journal:  Ann Surg Oncol       Date:  2009-10-30       Impact factor: 5.344

8.  Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase?

Authors:  Yasser H Shaib; Jessica A Davila; Kathryn McGlynn; Hashem B El-Serag
Journal:  J Hepatol       Date:  2004-03       Impact factor: 25.083

9.  Intra-arterial therapy for advanced intrahepatic cholangiocarcinoma: a multi-institutional analysis.

Authors:  Omar Hyder; J Wallis Marsh; Riad Salem; Elena N Petre; Sanjeeva Kalva; Eleni Liapi; David Cosgrove; Donielle Neal; Ihab Kamel; Andrew X Zhu; Constantinos T Sofocleous; Jean-Francois H Geschwind; Timothy M Pawlik
Journal:  Ann Surg Oncol       Date:  2013-07-12       Impact factor: 5.344

10.  Yttrium-90 radioembolization for unresectable standard-chemorefractory intrahepatic cholangiocarcinoma: survival, efficacy, and safety study.

Authors:  Shoaib Rafi; Sarat M Piduru; Bassel El-Rayes; John S Kauh; David A Kooby; Juan M Sarmiento; Hyun S Kim
Journal:  Cardiovasc Intervent Radiol       Date:  2012-09-07       Impact factor: 2.740

  10 in total
  5 in total

1.  Impact of adjuvant chemoradiation on survival in patients with resectable cholangiocarcinoma.

Authors:  Laura L Dover; Robert A Oster; Andrew M McDonald; Derek A DuBay; Thomas N Wang; Rojymon Jacob
Journal:  HPB (Oxford)       Date:  2016-08-16       Impact factor: 3.647

Review 2.  Selective internal radiation therapy with SIR-Spheres in hepatocellular carcinoma and cholangiocarcinoma.

Authors:  Eric A Wang; Scott R Broadwell; Ross J Bellavia; Jeff P Stein
Journal:  J Gastrointest Oncol       Date:  2017-04

Review 3.  Neoadjuvant treatment of biliary tract cancer: state-of-the-art and new perspectives.

Authors:  Marco Imperatori; Loretta D'Onofrio; Eleonora Marrucci; Francesco Pantano; Alice Zoccoli; Giuseppe Tonini
Journal:  Hepat Oncol       Date:  2015-11-30

Review 4.  The role of 90Y-radioembolization in downstaging primary and secondary hepatic malignancies: a systematic review.

Authors:  M N G J A Braat; M Samim; M A A J van den Bosch; M G E H Lam
Journal:  Clin Transl Imaging       Date:  2016-04-23

5.  Conversion Therapy of Intrahepatic Cholangiocarcinoma Is Associated with Improved Prognosis and Verified by a Case of Patient-Derived Organoid.

Authors:  Zhiwei Wang; Yun Jin; Yinghao Guo; Zhenhua Tan; Xiaoxiao Zhang; Dan Ye; Yuanquan Yu; Shuyou Peng; Lei Zheng; Jiangtao Li
Journal:  Cancers (Basel)       Date:  2021-03-09       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.